VivoSeq
Oncology

Stage III Cutaneous Melanoma AJCC V7

5

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Stage III Cutaneous Melanoma AJCC v7 is an early-stage landscape with 5 programs across 2 companies. The most active players are Bristol-Myers Squibb, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

PreclinicalSanofi logo

Sanofi

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Monoclonal antibody

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSProtein / enzyme133%

Monoclonal antibody leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 60% of 5 pipeline programs.

Analysis

Trial Status

2

clinical trials

Active, not recruiting2 · 100%

Clinical Trials

Trial Activity

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Active, not recruiting·National Cancer Institute (NCI)·Preclinical·NCT02339571·600 enrolled
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02196181·280 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)